RT Journal Article
SR Electronic
T1 Impact of the COVID-19 pandemic on treatment patterns for US patients with metastatic solid cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.22.21263964
DO 10.1101/2021.09.22.21263964
A1 Parikh, Ravi B.
A1 Takvorian, Samuel U.
A1 Vader, Daniel
A1 Wileyto, E. Paul
A1 Clark, Amy S.
A1 Lee, Daniel J.
A1 Goyal, Gaurav
A1 Rocque, Gabrielle B.
A1 Dotan, Efrat
A1 Geynisman, Daniel M.
A1 Phull, Pooja
A1 Spiess, Philippe E.
A1 Kim, Roger Y.
A1 Davidoff, Amy J.
A1 Gross, Cary P.
A1 Neparidze, Natalia
A1 Miksad, Rebecca A.
A1 Calip, Gregory S.
A1 Hearn, Caleb M.
A1 Ferrell, Will
A1 Shulman, Lawrence N.
A1 Mamtani, Ronac
A1 Hubbard, Rebecca A.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/09/23/2021.09.22.21263964.abstract
AB Background The COVID-19 pandemic has led to delays in patients seeking care for life-threatening conditions; however, its impact on treatment patterns for patients with metastatic cancer is unknown. We assessed the COVID-19 pandemic’s impact on time to treatment initiation (TTI) and treatment selection for patients newly diagnosed with metastatic solid cancer.Methods We used an electronic health record-derived longitudinal database curated via technology-enabled abstraction to identify 14,136 US patients newly diagnosed with de novo or recurrent metastatic solid cancer between January 1 and July 31 in 2019 or 2020. Patients received care at ∼280 predominantly community-based oncology practices. Controlled interrupted time series analyses assessed the impact of the COVID-19 pandemic period (April-July 2020) on TTI, defined as the number of days from metastatic diagnosis to receipt of first-line systemic therapy, and use of myelosuppressive therapy.Results The adjusted probability of treatment within 30 days of diagnosis [95% confidence interval] was similar across periods: January-March 2019 41.7% [32.2%, 51.1%]; April-July 2019 42.6% [32.4%, 52.7%]; January-March 2020 44.5% [30.4%, 58.6%]; April-July 2020 46.8% [34.6%, 59.0%]; adjusted percentage-point difference-in-differences 1.4% [-2.7%, 5.5%]. Among 5,962 patients who received first-line systemic therapy, there was no association between the pandemic period and use of myelosuppressive therapy (adjusted percentage-point difference-in-differences 1.6% [-2.6%, 5.8%]). There was no meaningful effect modification by cancer type, race, or age.Conclusions Despite known pandemic-related delays in surveillance and diagnosis, the COVID-19 pandemic did not impact time to treatment initiation or treatment selection for patients with metastatic solid cancers.Competing Interest StatementRavi Parikh and Ronac Mamtani have received reimbursement from Flatiron, Inc. for travel and speaking. Rebecca Miksad and Gregory Calip report employment at Flatiron Health, Inc. There are no other conflicts of interest relevant to this submitted work.Funding StatementThe funders had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Pennsylvania's Perelman School of Medicine IRB approved this studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll de-identified data generated or analyzed during this study is available upon request.